USMCA Watch: Eli Lilly Exports Slip, Pfizer Dosed Up As Drug Rules Are Abandoned December 5, 2019 The administration of President Donald Trump may be willing to drop proposals related to standardized biologic drug patent lengths in order to secure passage of the U.S.-Mexico-Canada Agreement, USMCA, through the U.S. House of Representatives. Setting patent protections to 10 years across the... Read more →
Novo and Lilly Face Tough Growth in Diabetes, Trade Data Shows December 2, 2016 The global prevalence of diabetes is growing, but can be a tough sector for pharmaceutical companies to make money in as recent results from Novo Nordisk and Eli Lilly demonstrate. Panjiva data shows that U.S. imports of insulin and related equipment fell 15% in the third quarter in dollar ter... Read more →